MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $175.14M |
| Gross Profit (TTM) | $-1.30M |
| EBITDA | $-32.17M |
| Operating Margin | -42.20% |
| Return on Equity | -225.90% |
| Return on Assets | -8.05% |
| Revenue/Share (TTM) | $2.76 |
| Book Value | $0.67 |
| Price-to-Book | 3.30 |
| Price-to-Sales (TTM) | 0.85 |
| EV/Revenue | 0.0183 |
| EV/EBITDA | -1.54 |
| Quarterly Earnings Growth (YoY) | -70.40% |
| Quarterly Revenue Growth (YoY) | 378.00% |
| Shares Outstanding | $63.70M |
| Float | $56.41M |
| % Insiders | 3.49% |
| % Institutions | 77.07% |
Volatility is currently expanding
ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D.
ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) directed against an undisclosed target, in patients with advanced solid tumors. “MGC030 demonstrated encouraging antitumor activity in multiple preclinical models, and we look forward to advancing this product candidate through the Phase 1 study.
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. Gilead's recent activity on multiple TCEs and MacroGenics' negative enterprise value suggest partnership is under appreciated & undervalued.
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MGNX and any ticker you trade — then tracks every position and per-strategy win rate.
